KROS vs SRRK
KROS: Clinical-stage biotech developing TGF-beta-targeting protein therapeutics for rare neuromuscular and hematologic diseases with one Phase 3 program licensed to Takeda. SRRK: Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate apitegromab anticipated for regulatory approval in 2026.
Side-by-side fundamentals
| Metric | KROS | SRRK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.21 | $48.30 | |
| Market cap as of 2026-07-23 | $202M | $5.9B | |
| P/E as of 2026-07-23 | 2.32 | n/a | |
| PEG as of 2026-07-23 | -0.00 | -0.40 | SRRK lower |
| Net margin as of 2026-07-23 | -256.6% | -237.0% | SRRK higher |
| Operating margin as of 2026-07-23 | -332.6% | -231.8% | SRRK higher |
| ROE as of 2026-07-23 | -17.0% | -162.9% | KROS higher |
| ROA as of 2026-07-23 | -15.8% | -96.3% | KROS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.71 | KROS lower |
| Revenue growth (YoY) as of 2026-07-23 | -84.5% | n/a | |
| Beta as of 2026-07-23 | 1.01 | 0.65 | |
| 1-year return as of 2026-07-22 close | -23.4% | +20.8% | SRRK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.